Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients

Jérôme Hadjadj, Nader Yatim, Laura Barnabei, Aurélien Corneau, Jeremy Boussier, Nikaïa Smith, Hélène Péré, Bruno Charbit, Vincent Bondet, Camille Chenevier-Gobeaux, Paul Breillat, Nicolas Carlier, Rémy Gauzit, Caroline Morbieu, Frédéric Pène, Nathalie Marin, Nicolas Roche, Tali-Anne Szwebel, Sarah H Merkling, Jean-Marc Treluyer, David Veyer, Luc Mouthon, Catherine Blanc, Pierre-Louis Tharaux, Flore Rozenberg, Alain Fischer, Darragh Duffy, Frédéric Rieux-Laucat, Solen Kernéis, Benjamin Terrier, Jérôme Hadjadj, Nader Yatim, Laura Barnabei, Aurélien Corneau, Jeremy Boussier, Nikaïa Smith, Hélène Péré, Bruno Charbit, Vincent Bondet, Camille Chenevier-Gobeaux, Paul Breillat, Nicolas Carlier, Rémy Gauzit, Caroline Morbieu, Frédéric Pène, Nathalie Marin, Nicolas Roche, Tali-Anne Szwebel, Sarah H Merkling, Jean-Marc Treluyer, David Veyer, Luc Mouthon, Catherine Blanc, Pierre-Louis Tharaux, Flore Rozenberg, Alain Fischer, Darragh Duffy, Frédéric Rieux-Laucat, Solen Kernéis, Benjamin Terrier

Abstract

Coronavirus disease 2019 (COVID-19) is characterized by distinct patterns of disease progression that suggest diverse host immune responses. We performed an integrated immune analysis on a cohort of 50 COVID-19 patients with various disease severity. A distinct phenotype was observed in severe and critical patients, consisting of a highly impaired interferon (IFN) type I response (characterized by no IFN-β and low IFN-α production and activity), which was associated with a persistent blood viral load and an exacerbated inflammatory response. Inflammation was partially driven by the transcriptional factor nuclear factor-κB and characterized by increased tumor necrosis factor-α and interleukin-6 production and signaling. These data suggest that type I IFN deficiency in the blood could be a hallmark of severe COVID-19 and provide a rationale for combined therapeutic approaches.

Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Figures

Fig. 1. Phenotyping of peripheral blood leukocytes…
Fig. 1. Phenotyping of peripheral blood leukocytes in patients with SARS-CoV-2 infection.
(A) Lymphocyte counts in whole blood from COVID-19 patients were analyzed between days 8 and 12 after onset of first symptoms, according to disease severity. (B) viSNE map of blood leukocytes after exclusion of granulocytes, stained with 30 markers and measured with mass cytometry. Cells are automatically separated into spatially distinct subsets according to the combination of markers that they express. LTgd, γδ T cell; MAIT, mucosal-associated invariant T cell; LB, B lymphocyte. (C) viSNE map colored according to cell density across disease severity (classified as healthy controls, mild to moderate, severe, and critical). Red indicates the highest density of cells. (D) Absolute number of CD3+ T cells, CD8+ T cells, and CD3–CD56+ NK cells in peripheral blood from COVID-19 patients, according to disease severity. (E and F) Proportions (frequencies) of lymphocyte subsets from COVID-19 patients. (E) Proportions of CD3+ T cells among lymphocytes, CD8+ T cells among CD3+ T cells, and NK cells among lymphocytes. (F) Proportions of CD19+ B cells among lymphocytes and CD38hi CD27hi plasmablasts among CD19+ B cells. (G) Analysis of the functional status of specific T cell subsets and NK cells based on the expression of activation (CD38, HLA-DR) and exhaustion (PD-1, Tim-3) markers. In (D) to (G), data indicate median. Each dot represents a single patient. P values were determined with the Kruskal-Wallis test, followed by Dunn’s post-test for multiple group comparisons with median reported; *P < 0.05; **P < 0.01; ***P < 0.001.
Fig. 2. Immunological transcriptional signature of SARS-CoV-2…
Fig. 2. Immunological transcriptional signature of SARS-CoV-2 infection.
RNA extracted from patient whole blood and RNA counts of 574 genes were determined by means of direct probe hybridization, using the Nanostring nCounter Human Immunology_v2 kit. (A) Heatmap representation of all genes, ordered by hierarchical clustering. Healthy controls (n = 13 patients), mild to moderate (n = 11 patients), severe (n = 10 patients), and critical (n = 11 patients). Up-regulated genes are shown in red, and down-regulated genes are shown in blue. (B) Volcano plots depicting log10 (P value) and log2 (fold change), as well as z value for each group comparison (supplementary materials, materials and methods). Gene expression comparisons allowed the identification of significantly differentially expressed genes between severity grades (heathy controls versus mild to moderate, 216 genes; mild to moderate versus severe, 43 genes; severe versus critical, 0 genes). (C) (Left) PCA of the transcriptional data. (Middle and right) Kinetic plots showing mean normalized values for each gene and severity grade, where each gray line corresponds to one gene. Median values over genes for each severity grade are plotted in black. Gene set enrichment analysis of pathways enriched in PC1 and PC2 are depicted under corresponding kinetic plot.
Fig. 3. Impaired type I IFN response…
Fig. 3. Impaired type I IFN response in patients with severe SARS-CoV-2 infection.
(A) Heatmap showing expression of type I IFN-related genes by using the reverse transcription- and PCR-free Nanostring nCounter technology in patients with mild-to-moderate (n = 11), severe (n = 10), and critical (n = 11) SARS-CoV2 infection, and healthy controls (n = 13). Up-regulated genes are shown in red, and down-regulated genes are shown in blue. (B) ISG score based on expression of six genes (IFI44L, IFI27, RSAD2, SIGLEC1, IFIT1, and IS15) measured with quantitative RT-PCR in whole blood cells from mild to moderate (n = 14), severe (n = 15), and critical (n = 17) patients and healthy controls (n = 18). (C) IFN-α2 (fg/ml) concentration evaluated by use of Simoa and (D) IFN activity in plasma according to clinical severity. (E) Mild to moderate (n = 14) and severe patients (n = 16) were separated in two groups depending on the clinical outcome, namely critical worsening requiring mechanical ventilation (to denote severe status). (Left) ISG score and (right) IFN-α2 plasma concentration are shown. (F) Time-dependent IFN-α2 concentrations are shown according to severity group. (G) Quantification of plasmacytoid dendritic cells (pDCs) as a percentage of PBMCs and as cells/milliliter according to severity group. (H) ISG score before and after stimulation of whole blood cells by IFN-α (103UI/ml for 3 hours). (I) Viral loads in nasal swabs estimated by means of RT-PCR and expressed in cycle threshold (Ct) and blood viral load evaluated by means of digital PCR. In (B) and (E), ISG score results represent the fold-increased expression compared with the mean of unstimulated controls and are normalized to GAPDH (glyceraldehyde phosphate dehydrogenase). In (B) to (I), data indicate median. Each dot represents a single patient. P values were determined with the Kruskal-Wallis test, followed by Dunn’s post-test for multiple group comparisons and the Mann-Whitney test for two group comparisons with median reported; *P < 0.05; **P < 0.01; ***P < 0.001.
Fig. 4. Immune profiling in patients with…
Fig. 4. Immune profiling in patients with severe and critical SARS-CoV-2 infection.
(A) Heatmap showing the expression of cytokines and chemokines that are significantly different in severe and critical patients, ordered by hierarchical clustering. Included are healthy controls (n = 13) and mild to moderate (n = 11), severe (n = 10), and critical (n = 11) patients. Up-regulated genes are shown in red, and down-regulated genes are shown in blue. (B) IL-6, (C) TNF-α, (D) IL-1β, and (E) IL-10 proteins were quantified in the plasma of patients by using Simoa technology or a clinical-grade ELISA assay (supplementary materials, materials and methods). Each group includes n = 10 to 18 patients. The dashed line indicates the limit of detection (LOD). (F) Kinetic plots showing mean normalized value for each gene and severity grade. Each gray line corresponds to one gene belonging to the NF-κB pathway. Median values over genes for each severity grade are plotted in black. (G) Plasma quantification of RIPK-3. Each group included n = 10 patients. (H) Absolute RNA count for (left) CXCR2, (middle) CXCL2 protein plasma concentration measured with Luminex technology, and (right) blood neutrophil count depending on severity group. The dashed line indicates the upper normal limit. Each group includes n = 10 to 13 patients. (I) Absolute RNA count for (left) CCR2; (middle left) CCL2 protein plasma concentration measured by Luminex technology; and (middle right) blood monocyte count depending on severity group. The dashed lines depict the normal range. (Right) The percentage of nonclassical monocytes, depending on severity grade. Each group shows n = 10 to 18 patients. RNA data are extracted from the Nanostring nCounter analysis (supplementary materials, materials and methods). In (B) to (I), data indicate median. Each dot represents a single patient. P values were determined with the Kruskal-Wallis test, followed by Dunn’s post-test for multiple group comparisons with median reported; *P < 0.05; **P < 0.01; ***P < 0.001.

References

    1. Guan W.-J., Ni Z.-Y., Hu Y., Liang W.-H., Ou C.-Q., He J.-X., Liu L., Shan H., Lei C.-L., Hui D. S. C., Du B., Li L.-J., Zeng G., Yuen K.-Y., Chen R.-C., Tang C.-L., Wang T., Chen P.-Y., Xiang J., Li S.-Y., Wang J.-L., Liang Z.-J., Peng Y.-X., Wei L., Liu Y., Hu Y.-H., Peng P., Wang J.-M., Liu J.-Y., Chen Z., Li G., Zheng Z.-J., Qiu S.-Q., Luo J., Ye C.-J., Zhu S.-Y., Zhong N.-S., China Medical Treatment Expert Group for Covid-19 , Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 382, 1708–1720 (2020). 10.1056/NEJMoa2002032
    1. Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X., Cheng Z., Yu T., Xia J., Wei Y., Wu W., Xie X., Yin W., Li H., Liu M., Xiao Y., Gao H., Guo L., Xie J., Wang G., Jiang R., Gao Z., Jin Q., Wang J., Cao B., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497–506 (2020). 10.1016/S0140-6736(20)30183-5
    1. Salje H., Tran Kiem C., Lefrancq N., Courtejoie N., Bosetti P., Paireau J., Andronico A., Hozé N., Richet J., Dubost C.-L., Le Strat Y., Lessler J., Levy-Bruhl D., Fontanet A., Opatowski L., Boelle P.-Y., Cauchemez S., Estimating the burden of SARS-CoV-2 in France. Science eabc3517 (2020). 10.1126/science.abc3517
    1. Chow E. J., Doyle J. D., Uyeki T. M., Influenza virus-related critical illness: Prevention, diagnosis, treatment. Crit. Care 23, 214 (2019). 10.1186/s13054-019-2491-9
    1. Wu C., Chen X., Cai Y., Xia J., Zhou X., Xu S., Huang H., Zhang L., Zhou X., Du C., Zhang Y., Song J., Wang S., Chao Y., Yang Z., Xu J., Zhou X., Chen D., Xiong W., Xu L., Zhou F., Jiang J., Bai C., Zheng J., Song Y., Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern. Med. 10.1001/jamainternmed.2020.0994 (2020). 10.1001/jamainternmed.2020.0994
    1. Li Q., Guan X., Wu P., Wang X., Zhou L., Tong Y., Ren R., Leung K. S. M., Lau E. H. Y., Wong J. Y., Xing X., Xiang N., Wu Y., Li C., Chen Q., Li D., Liu T., Zhao J., Liu M., Tu W., Chen C., Jin L., Yang R., Wang Q., Zhou S., Wang R., Liu H., Luo Y., Liu Y., Shao G., Li H., Tao Z., Yang Y., Deng Z., Liu B., Ma Z., Zhang Y., Shi G., Lam T. T. Y., Wu J. T., Gao G. F., Cowling B. J., Yang B., Leung G. M., Feng Z., Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N. Engl. J. Med. 382, 1199–1207 (2020). 10.1056/NEJMoa2001316
    1. Grasselli G., Zangrillo A., Zanella A., Antonelli M., Cabrini L., Castelli A., Cereda D., Coluccello A., Foti G., Fumagalli R., Iotti G., Latronico N., Lorini L., Merler S., Natalini G., Piatti A., Ranieri M. V., Scandroglio A. M., Storti E., Cecconi M., Pesenti A., Nailescu A., Corona A., Zangrillo A., Protti A., Albertin A., Forastieri Molinari A., Lombardo A., Pezzi A., Benini A., Scandroglio A. M., Malara A., Castelli A., Coluccello A., Micucci A., Pesenti A., Sala A., Alborghetti A., Antonini B., Capra C., Troiano C., Roscitano C., Radrizzani D., Chiumello D., Coppini D., Guzzon D., Costantini E., Malpetti E., Zoia E., Catena E., Agosteo E., Barbara E., Beretta E., Boselli E., Storti E., Harizay F., Della Mura F., Lorini F. L., Donato Sigurtà F., Marino F., Mojoli F., Rasulo F., Grasselli G., Casella G., De Filippi G., Castelli G., Aldegheri G., Gallioli G., Lotti G., Albano G., Landoni G., Marino G., Vitale G., Battista Perego G., Evasi G., Citerio G., Foti G., Natalini G., Merli G., Sforzini I., Bianciardi L., Carnevale L., Grazioli L., Cabrini L., Guatteri L., Salvi L., Dei Poli M., Galletti M., Gemma M., Ranucci M., Riccio M., Borelli M., Zambon M., Subert M., Cecconi M., Mazzoni M. G., Raimondi M., Panigada M., Belliato M., Bronzini N., Latronico N., Petrucci N., Belgiorno N., Tagliabue P., Cortellazzi P., Gnesin P., Grosso P., Gritti P., Perazzo P., Severgnini P., Ruggeri P., Sebastiano P., Covello R. D., Fernandez-Olmos R., Fumagalli R., Keim R., Rona R., Valsecchi R., Cattaneo S., Colombo S., Cirri S., Bonazzi S., Greco S., Muttini S., Langer T., Alaimo V., Viola U., COVID-19 Lombardy ICU Network , Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. JAMA 323, 1574 (2020). 10.1001/jama.2020.5394
    1. Mehta P., McAuley D. F., Brown M., Sanchez E., Tattersall R. S., Manson J. J.; HLH Across Speciality Collaboration, UK , COVID-19: Consider cytokine storm syndromes and immunosuppression. Lancet 395, 1033–1034 (2020). 10.1016/S0140-6736(20)30628-0
    1. Amir A. D., Davis K. L., Tadmor M. D., Simonds E. F., Levine J. H., Bendall S. C., Shenfeld D. K., Krishnaswamy S., Nolan G. P., Pe’er D., viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia. Nat. Biotechnol. 31, 545–552 (2013). 10.1038/nbt.2594
    1. Müller U., Steinhoff U., Reis L. F., Hemmi S., Pavlovic J., Zinkernagel R. M., Aguet M., Functional role of type I and type II interferons in antiviral defense. Science 264, 1918–1921 (1994). 10.1126/science.8009221
    1. Jeremiah N., Neven B., Gentili M., Callebaut I., Maschalidi S., Stolzenberg M.-C., Goudin N., Frémond M.-L., Nitschke P., Molina T. J., Blanche S., Picard C., Rice G. I., Crow Y. J., Manel N., Fischer A., Bader-Meunier B., Rieux-Laucat F., Inherited STING-activating mutation underlies a familial inflammatory syndrome with lupus-like manifestations. J. Clin. Invest. 124, 5516–5520 (2014). 10.1172/JCI79100
    1. Rodero M. P., Decalf J., Bondet V., Hunt D., Rice G. I., Werneke S., McGlasson S. L., Alyanakian M.-A., Bader-Meunier B., Barnerias C., Bellon N., Belot A., Bodemer C., Briggs T. A., Desguerre I., Frémond M.-L., Hully M., van den Maagdenberg A. M. J. M., Melki I., Meyts I., Musset L., Pelzer N., Quartier P., Terwindt G. M., Wardlaw J., Wiseman S., Rieux-Laucat F., Rose Y., Neven B., Hertel C., Hayday A., Albert M. L., Rozenberg F., Crow Y. J., Duffy D., Detection of interferon α protein reveals differential levels and cellular sources in disease. J. Exp. Med. 214, 1547–1555 (2017). 10.1084/jem.20161451
    1. Lebon P., Ponsot G., Aicardi J., Goutières F., Arthuis M., Early intrathecal synthesis of interferon in herpes encephalitis. Biomedicine 31, 267–271 (1979).
    1. Reizis B., Plasmacytoid Dendritic Cells: Development, Regulation, and Function. Immunity 50, 37–50 (2019). 10.1016/j.immuni.2018.12.027
    1. Z. Zhou, L. Ren, L. Zhang, J. Zhong, Y. Xiao, Z. Jia, L. Guo, J. Yang, C. Wang, S. Jiang, D. Yang, G. Zhang, H. Li, F. Chen, Y. Xu, M. Chen, Z. Gao, J. Yang, J. Dong, B. Liu, X. Zhang, W. Wang, K. He, Q. Jin, M. Li, J. Wang, Overly exuberant innate immune response to SARS-CoV-2 infection. (2020); available at 10.2139/ssrn.3551623.10.2139/ssrn.3551623
    1. Pedersen S. F., Ho Y.-C., SARS-CoV-2: A storm is raging. J. Clin. Invest. 130, 2202–2205 (2020). 10.1172/JCI137647
    1. Chen G., Wu D., Guo W., Cao Y., Huang D., Wang H., Wang T., Zhang X., Chen H., Yu H., Zhang X., Zhang M., Wu S., Song J., Chen T., Han M., Li S., Luo X., Zhao J., Ning Q., Clinical and immunological features of severe and moderate coronavirus disease 2019. J. Clin. Invest. 130, 2620–2629 (2020). 10.1172/JCI137244
    1. Rehwinkel J., Gack M. U., RIG-I-like receptors: Their regulation and roles in RNA sensing. Nat. Rev. Immunol. (2020). 10.1038/s41577-020-0288-3
    1. Liu S.-Y., Sanchez D. J., Aliyari R., Lu S., Cheng G., Systematic identification of type I and type II interferon-induced antiviral factors. Proc. Natl. Acad. Sci. U.S.A. 109, 4239–4244 (2012). 10.1073/pnas.1114981109
    1. Heinonen S., Velazquez V. M., Ye F., Mertz S., Acero-Bedoya S., Smith B., Bunsow E., Garcia-Mauriño C., Oliva S., Cohen D. M., Moore-Clingenpeel M., Peeples M. E., Ramilo O., Mejias A., Immune profiles provide insights into respiratory syncytial virus disease severity in young children. Sci. Transl. Med. 12, eaaw0268 (2020). 10.1126/scitranslmed.aaw0268
    1. Blanco-Melo D., Nilsson-Payant B. E., Liu W.-C., Uhl S., Hoagland D., Møller R., Jordan T. X., Oishi K., Panis M., Sachs D., Wang T. T., Schwartz R. E., Lim J. K., Albrecht R. A., tenOever B. R., Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell 181, 1036–1045.e9 (2020). 10.1016/j.cell.2020.04.026
    1. Terán-Cabanillas E., Hernández J., Role of leptin and SOCS3 in inhibiting the type I interferon response during obesity. Inflammation 40, 58–67 (2017). 10.1007/s10753-016-0452-x
    1. Galkina E., Ley K., Immune and inflammatory mechanisms of atherosclerosis. Annu. Rev. Immunol. 27, 165–197 (2009). 10.1146/annurev.immunol.021908.132620
    1. Ciancanelli M. J., Huang S. X. L., Luthra P., Garner H., Itan Y., Volpi S., Lafaille F. G., Trouillet C., Schmolke M., Albrecht R. A., Israelsson E., Lim H. K., Casadio M., Hermesh T., Lorenzo L., Leung L. W., Pedergnana V., Boisson B., Okada S., Picard C., Ringuier B., Troussier F., Chaussabel D., Abel L., Pellier I., Notarangelo L. D., García-Sastre A., Basler C. F., Geissmann F., Zhang S.-Y., Snoeck H.-W., Casanova J.-L., Infectious disease. Life-threatening influenza and impaired interferon amplification in human IRF7 deficiency. Science 348, 448–453 (2015). 10.1126/science.aaa1578
    1. Clohisey S., Baillie J. K., Host susceptibility to severe influenza A virus infection. Crit. Care 23, 303 (2019). 10.1186/s13054-019-2566-7
    1. Prokunina-Olsson L., Alphonse N., Dickenson R. E., Durbin J. E., Glenn J. S., Hartmann R., Kotenko S. V., Lazear H. M., O’Brien T. R., Odendall C., Onabajo O. O., Piontkivska H., Santer D. M., Reich N. C., Wack A., Zanoni I., COVID-19 and emerging viral infections: The case for interferon-λ. J. Exp. Med. 217, e20200653 (2020). 10.1084/jem.20200653
    1. Roumier M., Paule R., Groh M., Vallee A., Ackermann F., medRxiv, 2020.04.20.20061861 [Preprint] 22 April 2020. 10.1101/2020.04.20.20061861.10.1101/2020.04.20.20061861
    1. Feldmann M., Maini R. N., Woody J. N., Holgate S. T., Winter G., Rowland M., Richards D., Hussell T., Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed. Lancet 395, 1407–1409 (2020). 10.1016/S0140-6736(20)30858-8
    1. Bost P., Giladi A., Liu Y., Bendjelal Y., Xu G., David E., Blecher-Gonen R., Cohen M., Medaglia C., Li H., Deczkowska A., Zhang S., Schwikowski B., Zhang Z., Amit I., Host-viral infection maps reveal signatures of severe COVID-19 patients. Cell 181, 1475–1488.e12 (2020). 10.1016/j.cell.2020.05.006
    1. Yang X., Yu Y., Xu J., Shu H., Xia J., Liu H., Wu Y., Zhang L., Yu Z., Fang M., Yu T., Wang Y., Pan S., Zou X., Yuan S., Shang Y., Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational study. Lancet Respir. Med. 8, 475–481 (2020). 10.1016/S2213-2600(20)30079-5
    1. Vandesompele J., De Preter K., Pattyn F., Poppe B., Van Roy N., De Paepe A., Speleman F., Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 3, H0034 (2002). 10.1186/gb-2002-3-7-research0034
    1. Rasch D., Teuscher F., Guiard V., How robust are tests for two independent samples? J. Stat. Plan. Inference 137, 2706–2720 (2007). 10.1016/j.jspi.2006.04.011
    1. Darnell M. E. R., Taylor D. R., Evaluation of inactivation methods for severe acute respiratory syndrome coronavirus in noncellular blood products. Transfusion 46, 1770–1777 (2006). 10.1111/j.1537-2995.2006.00976.x

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit